Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Americas
Law firm Merchant & Gould has hired Alireza Behrooz as a partner in the firm’s chemical and life sciences group in Washington, DC.   10 December 2015
AstraZeneca agrees $380m Entocort deal
Americas
AstraZeneca has agreed to let distributor Perrigo Company sell its Entocort (budesonide) drug.   9 December 2015
Sandoz accused of infringing 11 AndroGel patents
Generics
Unimed Pharmaceuticals, a subsidiary of life sciences company AbbVie, has slammed generics maker Sandoz with a lawsuit alleging infringement of 11 of its patents.   8 December 2015
Americas
The US government has asked pharmaceutical company Mylan to testify with information on the price of a generic antibiotic product it makes.   7 December 2015
Americas
Valeant Pharmaceuticals has slammed Allergan’s attempt to market a generic version of its Relistor (methylnaltrexone bromide) drug.   4 December 2015
Americas
There were no surprises, but plenty of alarms yesterday following the US Court of Appeals for the Federal Circuit’s decision to reject Sequenom’s request for a re-hearing of its dispute with Ariosa Diagnostics en banc.   3 December 2015
Americas
The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc.   2 December 2015
Big Pharma
Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.   2 December 2015
Medtech
The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.   1 December 2015
Americas
A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite.   30 November 2015